Skip to main content

Table 4 Characteristics of severe P. ovale disease

From: A systematic review of the clinical presentation, treatment and relapse characteristics of human Plasmodium ovale malaria

Authors

Diagnostics

Parasitaemia

Body temperature (°C)

Features of severity

Treatment

Concomitant medication

Outcome

Comment

Tomar et al. [61]

MIC + PCR

39

Bilirubin >50 µm/l, creatinine >265 µm/l, systolic blood pressure <80 mmHg, hemoglobinuria

Artesunate iv

Ceftriaxone iv, antipyretics

Survival without sequelae

 

Lemmerer et al. [62]

MIC

40.5

Splenic rupture

Chloroquine, 2325 mg po over 2 days

Survival with sequelae

 

Strydom et al. [36]

MIC + PCR

1.4%

39.5

Bilirubin >50 µm/l, systolic blood pressure <80 mmHg

Quinine, 600 mg iv eight hourly and doxycycline 100 mg twelve hourly

Ceftriaxone

Survival without sequelae

 

Rojo-Marcos et al. [24]

MIC + PCR (microscopy neg, PCR positive)

Nega

Hemoglobin <7 g/dla

Survival without sequelaea

 

MIC + PCR (microscopy neg, PCR positive)

Nega

Hemoglobin <7 g/dla

Survival without sequelaea

 

Lau et al. [8]

MIC + PCR

0.18%

40.8

Creatinine >265 µm/l, acidosis, ARDS

Chloroquine 150 mg base for 2 days, quinine for 1 day and artesunate for 7 days

Ceftriaxone, piperacillin/tazobactam, vancomycin, imipenem, meropenem

Death

The first antibiotic was started on day 4 despite negative blood cultures; Enterobacter cloacae was found on day 15 (nosocomial sepsis); seizures were described on day 17; atrial fibrillation on day 22; asystole on day 32

Hachimi et al. [42]

MIC

<0.2%

39

ARDS

Quinine

Death

History of tuberculosis 11 years ago

Lahlou et al. [41]

MIC

0.2%

ARDS

Quinine

Ciprofloxacin

Death

History of treated pulmonary tuberculosis 10 years ago

Roze et al. [63]

MIC

0.2%

ARDS

Chloroquine and quinine

Survival without sequelae

History of tuberous sclerosis and spontaneous pneumothorax

Coton et al. [64]

MIC

40

Acute pericarditis

Chloroquine 30 mg/kg over 6 days

Ketoprophen, omeprazol, aspirin

Survival without sequelae

 

Haydoura et al. [65]

MIC

1.1%

40

Oxygen saturation <92%, ARDS

Quinine iv for 7 days and doxycycline po for 7 days

Warfarin

Survival without sequelae

History of MTHFR, secondary portal vein thrombosis and severe lower gastrointestinal bleeding from hemorrhoids requiring 7 units of red blood cells

Cinquetti [66]

MIC + PCR

0.001%

39.5

Splenic infarction

Quinine 8 mg/kg iv three times daily

Survival with sequelae

 

Rojo-Marcos et al. [25]

MIC + PCR

6000 trophozoites + gametocytes/µl

40.5

ARDS

Chloroquine for 3 days

Survival without sequelae

History of diabetes mellitus and hypertension; incomplete left bundle block in the predose ECG followed by left ventricular hypertrophy in the day 30 ECG; presence of Mansonella perstans; nosocomial Acinetobacter baumanii in broncho-alveolar aspirate

Rubinstein et al. [67]

MIC

0.2%

Bilirubin >50 µm/l

Quinine for 7 days and doxycycline for 7 days

Survival without sequelae

 

Filler et al. [68]

MIC

Hemoglobin <7 g/dl, splenic rupture, cardiac arrest

Quinine sulfate and doxycycline, followed by quinidine iv

Death

History notably of MS

Lee et al. [69]

MIC

0.1%

39

Oxygen saturation <92%, pulmonary edema

Chloroquine

Survival without sequelae

Negative blood cultures

Patel [70]

MIC

Splenic rupture

Chloroquine

Survival with sequelae

 

Facer et al. [9]

MIC

1.8%

NA

Splenic rupture

NA

NA

Death

Diagnosis post mortem; absence of P. falciparum confirmed with “DNA analysis”

Monlun et al. [71]

MIC

41

Cardiomyopathy

Chloroquine 500 mg/day for 5 days

Survival without sequelae

Cardiomyopathy resolved without additional specific treatment

Bock [72]

MIC

Hemoglobin <7 g/dl

Mepacrine

Survival without sequelae

Case 2

MIC

40

Cardiac arrhythmia

Mepacrine

Survival without sequelae

Case 15

Fairley [73]

MIC

38.3

Hemoglobinuria

Mepacrine 0.1 g three times daily for 6 days and quinine bihydrochloride 7.5 g/day iv for 5 days

Saline

Survival without sequelae

 
  1. MIC microscopy, PCR polymerase chain reaction, po per os, iv intravenous, NA not applicable, ARDS acute respiratory distress syndrome, MTHFR methylentetrahydrofolate reductase defect, MS multiple sclerosis, not mentioned in the original publication
  2. aInformation provided by the author